Amarin Corporation plc is a neuroscience company focused on the development and commercialization of novel drugs for the treatment of neurological disorders affecting the central nervous system. Amarin is engaged in the continued development of Miraxion (formerly LAX-101) in Huntington's Disease, which is in Phase III in the United States. Huntington's disease is a neurodegenerative disease characterized by movement disorder, dementia and psychiatric disturbance. The Company seeks to directly commercialize its neurology products in the United States, while out-licensing or partnering its pipeline globally for indications outside neurology. Amarin also intends to leverage its development capabilities by supplementing its internal development pipeline through acquiring and/or in-licensing products for direct marketing by the Company in its core United States market and selected field of neuroscience.